



Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020

Laura Bubba¹, Peter Simmonds²,
Thea K Fischer^{3,4*}, Heli Harvala^{5,6*},
on behalf of the ESCV & ENPEN
study group

¹ Department of Biomedical Science for Health,
University of Milan, Milan, Italy

² Nuffield Department of Medicine, University
of Oxford, Oxford, UK

³ Department of Clinical Research, University
hospital of Nordsjaelland, Hilleroed, Denmark

⁴ Department of Public Health, University of
Copenhagen, Copenhagen, Denmark

⁵ Microbiology Services, NHS Blood and
Transplant, London, UK

⁶ Division of Infection and Immunity, University
College London, London, UK

*Shared last authorship.

Background The SARS-CoV-2 pandemic spread across Europe from February 2020. While robust SARS-CoV-2 serological assays were quickly developed, only limited information on applied serological testing is available. We describe the extent and nature of SARS-CoV-2 serological testing used in Europe and assess the links between epidemiology, mitigation strategies applied and seroprevalence.

Methods An online questionnaire on SARS-CoV-2 serology was sent to the European Society of Clinical Virology and European Non-Polio Enterovirus Network members in September 2020. Data were analysed by comparing mitigation approaches, serological methods and seroprevalence studies performed.

Results About 100 000 laboratory confirmed cases identified between March and June 2020 were reported by 36 participating laboratories from 20 countries. All responders experienced mitigation strategies including lockdowns and other closures. All except one participant had introduced serological testing; most had validated their assays (n=29), but some had had difficulties in obtaining reference material. Most used commercial assays (n=35), measuring IgG response against the spike antigen. Serology was used primarily for diagnostic purposes (n=22) but also for convalescent plasma (n=13) and research studies (n=30). Seroprevalence studies targeted mainly health care workers (n=20; seroprevalence 5% to 22%) and general population (n=16; seroprevalence 0.88% to 5.6%). Basic demographic and clinical information were collected by most laboratories (n=28), whereas data on long-term outcomes were rarely collected.

Conclusions This is first study gathering systematic information on serological testing approaches implemented during the first pandemic wave in Europe.

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, in December 2019 [1]. It soon escalated into a pandemic which has to date as of 8 April 2021 affected more than 27 million people and been associated with more than 625 000 deaths in the European region [1]. SARS-CoV-2 associated disease termed as COVID-19 ranges from asymptomatic to mild upper respiratory track and gastrointestinal symptoms, to severe pneumonia, thrombosis, multi-organ failure and death [2].

Correspondence to:

Laura Bubba, PhD
Via Pascal 36
20133 Milan
Italy
laura.bubba@unimi.it

During the first pandemic wave in Europe, comprehensive mitigation strategies were implemented in many European countries in order to limit the spread of the novel SARS-CoV-2 and to protect health care systems from overwhelming numbers of very ill patients. These measures included national lockdowns and social isolation, enhanced border control and even closure of borders. At the same time, huge efforts were required from diagnostic virology laboratories and public health agencies to evaluate and introduce new molecular and serological methods for SARS-CoV-2 diagnostics in order to respond to the pandemic and provide on-going scientific support for the mitigation strategies introduced. For these reasons, population-based estimates for SARS-CoV-2 seroprevalence were, and still are, in high demand. Review of published data highlighted a generally low SARS-CoV-2 seroprevalence in Europe [3]. Nationwide seropositivity ranged from 2.5% in Italy [4] and 5% in Spain [5], despite the similar numbers of SARS-CoV-2 infections reported during the first wave [6]. However, seropositivity numbers should not be compared without adjusting for test sensitivity and specificity, highly dependent on the chosen target antigen and assay used. Furthermore, substantial variability in SARS-CoV-2 seropositivity was demonstrated in Spain. Highest seroprevalence rates exceeding 10% were measured in the areas with high prevalence of SARS-CoV-2 infection (ie, Madrid area) and among health care workers with likely greater exposure to the virus.

Serological tests are used for many purposes including estimating population exposures, retrospective diagnostics of SARS-CoV-2 infections, and identification of convalescent plasma donations containing high levels of SARS-CoV-2 antibodies [7].

A large number of serological assays have been released into European market since the first reports of SARS-CoV-2 infection in Wuhan. Commercially available serological assays can detect IgG, IgM or IgA alone or combination of all antibodies (total antibody). Existing assays target antibodies to the nucleocapsid and/or spike protein, sometimes including only the receptor-binding domain (RBD) part. Although fast development of commercial serological assays has been vital to our pandemic response, their performance including sensitivity and specificity has remained suboptimal at times [8]. However, no information is available, in our knowledge, about the European diagnostic laboratory approach to serology, including how commonly and which serological methods are used, and how these were validated. Furthermore, limited data are published on the quality of serological data collected and their completeness, which is needed in order to better understand the antibody response acquired as a result of SARS-CoV-2 infection.

We have evaluated the extent of serological SARS-CoV-2 testing and methods used in Europe so far and the quality and quantity of serological data collected during the first wave of pandemic. Mitigation and quarantine strategies applied have been also investigated in order to describe whether they affected the number of COVID-19 cases. These will provide essential European-wide baseline information which can be used to inform future policies and targeted public health strategies during the future pandemic waves and to evaluate vaccine immunization response.

METHODS

Data collection

A link to the online questionnaire was sent to all members of the European Society for Clinical Virology (ESCV) and European Non-Polio Enterovirus Network (ENPEN) in order to reach a good selection of clinical and public health virology laboratories on the European territory. One reminder letter was sent. Data were collected using the EU-survey platform. Questionnaire was opened 23rd September and closed 12th October.

Basic participant information was collected; this included whether their laboratory was performing diagnostic SARS-CoV-2 services and whether it was linked to hospital, university and/or national public health institution. The survey focused on the epidemiology of SARS-CoV-2 infections in the respondent's institution or country, and hence the number of SARS-CoV-2 infections diagnosed, and population size covered by that institution were captured (**Figure 1**). Data on mitigation and quarantine strategies applied were also collected. Details of serological testing methods applied in respondent's institution or country, including their details of their validation, use in diagnostic and different seroprevalence studies, was also collected. Data on serological testing performed was collected, including the estimated number of samples tested.

Data analyses

A descriptive analysis was undertaken by participant laboratory and country. The geographical distribution of laboratories by their main function in Europe were mapped.

Participant laboratories were asked to report the COVID-19 case definition in use during the study period.




Figure 1. Survey structure divided by the five sections of the survey, their specific content and the purpose of the section.

Responders also reported, information on the month when the highest number of confirmed SARS-CoV-2 cases, and this was compared with the timing of lockdown strategy applied. The estimated number of COVID-19 cases was compared to the length of mitigation strategies applied, in order to demonstrate whether to highest number of cases corresponded to the longest period of restrictions applied.

Serological methods reported by participant laboratory were divided into virus neutralisation, commercial and in-house assays. In addition, we collected and analysed the data on targets (ie, immunoglobulin class or antigenic target) and we recorded if the laboratories has performed the validation or verification of their serological assay, and if so, using how many samples. Serological testing was categorised into clinical diagnostics, testing of convalescent plasma donor to determine which donations contained high enough SARS-CoV-2 antibody levels to be used as a treatment for COVID-19 and seroprevalence studies (ie, serology was used to drive or support studies to determine the susceptibility of the population calculating the seroprevalence in a population).

For seroprevalence studies, we collected and analysed data on study population, design and size of the study.

Laboratories performing seroprevalence studies were asked to estimate the seroprevalence as the proportion of SARS-CoV-2 seropositives by the number of inhabitants, and the study population size when possible. The proportions reported were compared, analysing whether any significant differences were observed with χ^2 test, considering a $P < 0.05$ as statistically significant.

RESULTS

A total of 36 participant laboratories from 20 countries responded to this survey (**Table 1, Figure 2**). Portugal was represented with 6 participant laboratories, followed by Germany, Spain and Turkey which contributed with 3 participating laboratories and Denmark, Greece, Norway, Slovenia and Sweden with two participating

laboratories each. Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Iceland, Ireland, Italy, the Netherlands and Romania participated with one laboratory each. Eight countries reported the population covered from their laboratories and/or the number of beds accounted in their hospitals. Reported population size ranged from 700 bed hospital in Istanbul to 1616 beds in Freiburg, covering approximately from 500 000 and >1 000 000 inhabitants (**Table 1**).

The majority of laboratories participating in the survey were involved in both diagnostic work and research (20/36, 55%); these included university hospitals (5/20), national (9/20) or regional (3/20) public health institutes and university microbiological laboratories (3/20). The remaining were diagnostic hospital laboratories (11/16), private laboratory (1/16) or university departments (4/16) (**Table 1**).

Case-definition

Thirty-three out of 36 participating laboratories reported use of the COVID-19 case definition during the study period: in most cases viral RNA detection in nasal-pharyngeal specimen or secretions taken from the respiratory tract was considered sufficient to confirm a case (70%, 23/33), whereas the remaining responders defined a confirmed COVID-19 case only when clinical symptoms consistent with COVID-19 were reported in addition to molecular RNA detection (28%, 9/33). Case definition was not applicable for three responders (ie, private laboratories) and one participant did not describe a case definition. Notably, as the case definition might have changed for some locations during the first wave of the pandemic, coinciding with the study period, the most recent case definition was recorded.

Case numbers

Around 100 000 laboratory confirmed SARS-CoV-2 infections identified between 1st March and 31st June 2020 were reported by the 34 participant laboratories. However, it is important to note that this was an estimate only and the number of reported cases ranged from less than 10 reported by Bulgaria to more than 10 000 cases reported by participating laboratories in Denmark, Portugal, Spain and Sweden (**Table 1**). The highest number of infections were recorded in March by 11 laboratories from 6 countries and in April by 15 laboratories from 10 countries (**Table 1**). Only one participating laboratory recorded a peak number of cases in May (Portugal) and five in June. No such data were obtained from 4 laboratories.

Mitigation and quarantine strategies

Mitigation and quarantine strategies were reported by 33 participants. Sweden (reported by both participating laboratories) was the only country which did not apply any mitigation or lockdown during the first pandemic wave, but were instead recommending people to keep social distancing, avoid gathering with more than 50 people and restricting the access to care homes (**Table 1**). 30 out of the remaining 32 participant laboratories reported a national lockdown undertaken as mitigation strategy, with varying length. For 26 participating laboratories, it was possible to compare the timing of the peak of COVID-19 case detection and implementation of mitigation measures. It was observed that the peak number of cases were recorded one month after the introduction of mitigation measures by 42% of participant laboratories (11/26), by 39% (10/26) during the first month of lockdown, by 15% (4/26) the month after the end of lockdown and by 4% (1/26) during the last month of these actions (**Table 1**). Severity of mitigation strategies, such as the length of national lockdown was not always proportional to the number of cases reported. For instance, Bulgaria reported less than 10 cases, whereas over 10 000 cases were reported by the Danish participants. Despite the difference in reported number of SARS-CoV-2 infections, both countries applied four months of lockdown (**Table 1**). Six countries including Belgium, Croatia, Greece, Ireland, and Spain reported the use of local lockdowns in spite of the national lockdown in order to control the increasing numbers of SARS-CoV-2 infections in the affected areas (**Table 1**).

Most laboratories reported the use of 14-day isolation period for the close contacts of confirmed SARS-CoV-2 case (29/33) and some of them applied these also for the contacts of suspected SARS-CoV-2 case (20/33). All laboratories placed contacts into 14-day quarantine while waiting for the PCR result and that was also applied for foreign travel (17/33; **Table 1**).

Serological assays used

All except one laboratory had introduced at least one SARS-CoV-2 serological assay for routine work during the first pandemic wave (n=35), while the remaining laboratory was planning to introduce such a test. All of them had introduced commercial assay for SARS-CoV-2 serology, and one focused on live virus neutralisation

Table 1. List of kind of institutions, estimate number of COVID-19 confirmed cases identified during the study period, population served/number of hospital beds and mitigation and quarantine schemes applied from March to June 2020 by participant laboratories

COUNTRY	CITY (IN ORDER OF SUBMISSION)	INSTITUTION	PURPOSE LABORATORY ACTIVITY	POPULATION	TOTAL NUMBER OF CASES REPORTED (ESTIMATE)	PEAK MONTH	LOCKDOWNS IMPLEMENTATION				SCHOOL, OFFICE AND RESTAURANTS CLOSURE				QUARANTINE SCHEME			
							March	April	May	June	March	April	May	June	CONFIRMED CLOSE CONTACT	SUSPECTED CLOSE CONTACT	TRAVEL IN EU COUNTRIES	TRAVEL EXTRA EU COUNTRIES
Austria	Vienna	Hospital and University microbiology laboratory	Diagnostic and research	Not reported	101-1000	March	*	*	**	**	¶	¶	¶	**	<14 d, depending on swab results	<14 d, depending on swab results	<14 d, 14 d	<14 d, 14 d
Belgium	Bruges	Hospital microbiology laboratory	Diagnostic	Not reported	1000-5000	April	*	*	**	‡	**	**	**	¶	14 d, depending on swab results		14 d	14 d
Bosnia and Herzegovina	Sarajevo	Hospital and University microbiology laboratory	Diagnostic and research	1 331 310 people; 1464 beds	1000-5000	June	-	*	*	**	**	¶	¶	§	14 d			
Bulgaria	Sofia	National public health institute	Diagnostic and research	Not reported	<10	Not reported	*	*	*	*	¶	¶	¶	¶	>14 d, depending on swab/sero results	14 d, depending on swab/sero results	14 d, depending on swab/sero results	14 d, depending on swab/sero results
Croatia	Zagreb	National public health institute	Diagnostic and research	Not reported	1000-5000	April	*	*	*	‡	¶	¶	¶	§	14 d, depending on swab results		14 d	14 d
Czech Republic	Prague	National public health institute	Diagnostic and research	Not reported	101-1000	April	*	*	*	-	¶	¶	¶	**	<14 d	Depending on swab results	14 d	14 d
Denmark	Copenhagen	Hospital microbiology laboratory	Diagnostic	>1 000 000 people	1000-5000	April	*	*	*	‡	¶	¶	¶	¶	14 d	14 d	14 d	14 d
	Copenhagen and Hilleroed	National public health institute; University laboratory or research unit	Diagnostic and research	Not reported	>10 000	March	*	*	*	*	¶	¶	¶		14 d	14 d, depending on swab results	14 d	14 d
Germany	Kiel	Regional public health institute; Hospital and University microbiology laboratory	Diagnostic and research	Not reported	10-100	March	*	*	**	**	¶	¶	§	**	14 d	Depending on swab results	14 d	14 d
	Freiburg	Hospital and University microbiology laboratory	Diagnostic and research	1616 beds	101-1000	April	*	*	**	**	**	**	**	**	14 d, depending on swab results	Depending on swab results		
	Bonn	University microbiology laboratory	Research	Not reported	101-1000	March	*	*	**	**	¶	¶	**	**	14 d		14 d	14 d
Greece	Thessaloniki	University microbiology laboratory	Diagnostic and research	Not reported	101-1000	April	*	*	*	‡	**	¶	¶	¶	14 d	14 d	14 d	14 d
	Crete	Regional public health institute	Diagnostic and research	1640 beds	10-100	June	*	*	*	**	**	**	**	**	14 d	14 d	14 d	14 d

Table 1. Continued

COUNTRY	CITY (IN ORDER OF SUBMISSION)	INSTITUTION	PURPOSE LABORATORY ACTIVITY	POPULATION	TOTAL NUMBER OF CASES REPORTED (ESTIMATE)	PEAK MONTH	LOCKDOWNS IMPLEMENTATION				SCHOOL, OFFICE AND RESTAURANTS CLOSURE				QUARANTINE SCHEME			
							March	April	May	June	March	April	May	June	CONFIRMED CLOSE CONTACT	SUSPECTED CLOSE CONTACT	TRAVEL IN EU COUNTRIES	TRAVEL EXTRA EU COUNTRIES
Iceland	Reykjavík	Hospital microbiology laboratory	Diagnostic	Not reported	1000-5000	March	**	**	**	**			**	**	14 d	14 d	14 d	14 d
Ireland	Dublin	Hospital microbiology laboratory	Diagnostic	Not reported	1000-5000	April	*	*	*	+	**	**	**	**	14 d	14 d	14 d	14 d
Italy	Pavia	Regional public health institute; University laboratory or research unit	Diagnostic and research	Not reported	5000-10000	March	*	*	*	**	¶	¶	¶	§	14 d, depending swab/sero results	14 d, depending swab/sero results	14 d, depending swab/sero results	14 d, depending swab/sero results
The Netherlands	Tilburg	Hospital microbiology laboratory	Diagnostic	5000000 people; 1000 beds	1000-5000	April	*	*	**	**	¶	¶	**	**	14 d, depending swab/sero results	14 d, depending swab/sero results	<14 d	<14 d
Norway	Oslo	Hospital and University microbiology laboratory	Diagnostic and research	Not reported	1000-5000	March	*	*	**	**	¶	¶	**	**	14 d	14 d, depending on swab results	<14 d	<14 d
	Trondheim	Hospital microbiology laboratory	Diagnostic	470.000 people	101-1000	March	*	*	**	**	¶	¶	**	**	14 d	14 d	14 d	14 d
Portugal	Porto	University microbiology laboratory	Research	Not reported	Not reported	Not reported	*	*	*	**	¶	¶	¶	**	14 d	14 d		
	Mora	University laboratory or research unit; Community Pharmacy	Diagnostic and research	Not reported	10-100	Not reported					Not reported				14 d	14 d	Depending on swab results	Depending on swab results
	Lisbon 1	National public health institute; Hospital and University microbiology laboratory	Diagnostic and research	Not reported	101-1000	April	*	**	**	**	¶	¶	**	**	14 d	14 d	Depending on swab results	Depending on swab results
	Lisbon 2	National Institute of Health	Diagnostic and research	Not reported	>10000	May	*	*	*	**	¶	¶	¶	**	14 d	14 d	Depending on swab results	Depending on swab results
	Porto	National public health institute	Diagnostic and research	Not reported	10-100	April	*	*	**	**	¶	¶	¶	§	14 d			
	Penafiel	Private Laboratory Clinical Analysis	Diagnostic	Not reported	101-1000	June	*	*	*	**	¶	¶	¶	**	14 d	14 d		

Table 1. Continued

COUNTRY	CITY (IN ORDER OF SUBMISSION)	INSTITUTION	PURPOSE LABORATORY ACTIVITY	POPULATION	TOTAL NUMBER OF CASES REPORTED (ESTIMATE)	PEAK MONTH	LOCKDOWNS IMPLEMENTATION				SCHOOL, OFFICE AND RESTAURANTS CLOSURE				CONFIRMED CLOSE CONTACT	SUSPECTED CLOSE CONTACT	TRAVEL IN EU COUNTRIES	TRAVEL EXTRA EU COUNTRIES
							March	April	May	June	March	April	May	June				
Romania	Bucharest	Hospital microbiology laboratory	Diagnostic	Not reported	5000-10000	June	*	*	**	**	¶	¶	¶	¶	14 d	Depending on swab results	14 d	14 d
Slovenia	Ljubljana 1	Diagnostic laboratory at the National public health institute	Diagnostic and research	Not reported	10-100	April	*	*	**	**	¶	¶	**	**	14 d		14 d	14 d
	Ljubljana 2	Academic diagnostic microbiology laboratory	Diagnostic and research	Not reported	101-1000	March	*	*	**	**	¶	¶	**	**	<14 d		<14 d	<14 d
Spain	Barcelona 1	Hospital microbiology laboratory	Diagnostic	Not reported	1000-5000	March	*	*	*	**	¶	¶	¶	§	14 d	14 d		
	Barcelona 2	Hospital microbiology laboratory	Diagnostic	450 000 people; 1200 beds	>10000	March	*	*	‡	‡	¶	¶	¶	§	14 d	14 d		
	Madrid	National public health institute	Diagnostic and research	Not reported	Not reported	Not reported					Not reported					Not reported		
Sweden	Stockholm	Hospital microbiology laboratory	Diagnostic	Not reported	>10000	April	Recommendations on social distancing ie, working from home, max allowed gatherings 50 people, restricted access to caring facilities								Not reported			
	Lund	Hospital microbiology laboratory	Diagnostic	Not reported	1000-5000	June										Not reported		
Turkey	Istanbul	Hospital and University microbiology laboratory	Diagnostic and research	700 beds	5000-10000	April	*	*	*	**	¶	¶	¶	**	14 d	Depending on swab results	14 d	14 d
	Izmir	University microbiology laboratory	Research	1809 beds	101-1000	April	**	*	*	*	¶	¶	¶	¶	14 d	14 d	14 d	14 d
	Ankara	University microbiology laboratory	Diagnostic	1040 beds	1000-5000	April	**	†	†	**	**	¶	¶	¶	14 d, depending on swab results	14 d	14 d	14 d

d – day

*National, Regional and Local lockdowns.

†Regional and local lockdowns.

‡Local lockdowns only.

§School and office closure.

| Restaurant closure.

¶School, office and restaurant closure.

**No lockdown and/or closures applied.




Figure 2. Map of the 36 collaborating laboratories divided by purpose of laboratory work: 1) “diagnostic and research” (in green) include all laboratories belonging to university hospitals or hospitals including a research section; 2) “diagnostic” (in violet) include all hospital laboratories, private laboratories and national/regional reference centres that operate also as diagnostic laboratory; 3) “research” (in blue) consist of all university sites and laboratory mainly dedicated to research projects

testing (Kiel; **Table 2**). Among the commercial assays performed, Euroimmun ELISA was the most common (17 participating laboratories from 36), followed by Roche ($n=12$), Abbott ($n=10$), Diasorin ($n=7$) and Wantai ($n=7$; **Table 2**). Three laboratories used in-house assays and nine were performing neutralising antibody testing in addition to the commercial methods. These included neutralisation testing using live virus ($n=7$; three laboratories in Germany, one in Croatia, Italy and Norway), pseudotype (Ireland) or other surrogate neutralising antibody testing (Spain, **Table 2**).

Each laboratory using commercial or in-house serological assays reported availability to measure IgG response alone (3/36 laboratories) or together with other immunoglobulins (27/36); further testing included IgM (23/36) or IgA antibodies (12/36). Assays targeted most often the spike protein (S, $n=12$) but also nucleoprotein (N, $n=10$) or receptor binding domain of spike protein (RBD, $n=8$). Only two laboratory reported availability to measure antibody responses against all three target proteins (Austria and one Slovenian laboratory, **Table 2**).

Assay validation

29 out of 36 laboratories reported that their method had been validated before introduction into clinical use. Among the remaining seven laboratories, two reported that the internal validation performed by their testing system was sufficient enough for them and hence no further assessment was required. Two laboratories could not identify sufficient control material for validation, one relied on published validation data on the methods selected for use and one decided to introduce the emergency test for convalescent plasma donor screening without validation. The number of known positive and negative samples included in validation work varied from one sample each to over 500 samples. Four laboratories (14%) had included fewer than 15 samples in their validation panel.

Most laboratories reported the use of serum samples only (20 from 34 responses), whereas 12 laboratories also accepted plasma, one saliva and one plasma and saliva in addition to serum. Only one laboratory was limited to using plasma or capillary blood only.

Table 2. List of methods performed to detect SARS-CoV-2 antibodies and/or antigens and commercial assay in use during the study period, by participant laboratories, from March to June 2020

COUNTRY	CITY	ANTIBODY DETECTION				ANTIGENS			LIVE VIRUS NEUTRALISATION ASSAY	COMMERCIAL ASSAY DETAILS						IN-HOUSE ASSAYS	
		IgG	IgM	IgA	Total Ig	Spike	RBD	N		Euroimmun	Roche	Abbott	Diasorin	Wantai	NovaTec		Other
Austria	Vienna	x	x	x	x	x	x	x	x	x	x			x		x	x
Belgium	Bruges	x	x					x		x		x				x	x
Bosnia and Herzegovina	Sarajevo	x	x					x									x
Bulgaria	Sofia	x	x	x				x		x							
Croatia	Zagreb	x	x	x			x		x	x		x				x	x
Czech Republic	Prague	x	x	x				x	x	x							
Denmark	Copenhagen	x	x														x
	Copenhagen and Hilleroed	x	x											x			
Germany	Kiel								x [9]			No commercial kit in use					
	Freiburg	x							x	x							
	Bonn	x	x	x	x			x	x	x	x	x		x			x
Greece	Thessaloniki	x	x	x	x											x	x
	Crete					Not reported				x							
Iceland	Reykjavik					Not reported						x					
Ireland	Dublin	x	x						x*			x	x	x			
Italy	Pavia				x	x		x	x				x				
The Netherlands	Tilburg				x			x							x		
Norway	Oslo	x	x	x	x	x	x			x	x			x			x
	Trondheim				x			x	x	x		x			x		
Portugal	Porto	x	x										x				
	Mora	x	x										x				
	Lisbon 1	x	x								x		x				
	Lisbon 2	x	x	x	x	x	x			x					x		
	Porto	x	x														x
	Penafiel	x											x				
Romania	Bucharest	x	x														x
Slovenia	Ljubljana 1	x	x	x			x	x		x							x
	Ljubljana 2	x	x	x	x	x	x	x	x	x	x						
Spain	Barcelona 1	x	x									x				x	
	Barcelona 2	x			x	x		x		x	x		x				
	Madrid	x			x	x			x*	x	x	x					
Sweden	Stockholm	x					x	x						x			x
	Lund	x					x					x		x			x
Turkey	Istanbul	x	x	x	x					x	x	x					x
	Izmir	x			x	x		x		x	x						
	Ankara	x					x			x							
Total	37	30	23	12	11	12	7	10	9	17	12	10	7	7	4	14	3

*Pseudotype virus neutralisation assay [10].

Application of serological testing

Participating laboratories were asked to report the purpose of serological testing in use (see section *Serological assays used* above). In particular 30/36 laboratories declared to use SARS-CoV-2 serological testing as support for seroprevalence studies (Table 3), 22 laboratories as a diagnostic service, 13 laboratories performed serological testing to support collection of the convalescent plasma and 8 as part of larger studies, including also other methodologies of detection (Table 4).

Within these studies or in diagnostic routine, serological testing was used to confirm a past infection in patients without SARS-CoV-2 diagnosis (26 participants from 34), to prove acquired immunity to the infection (n = 15), to confirm past infection in those with a negative diagnosis (n = 15), to estimate the number of asymptomatic infections (n = 13) and to evaluate serological responses in immunocompromised patients (n = 10).

Seroprevalence studies performed used several different designs; the descriptive cross-sectional study design was most commonly used followed by cohort study, convenient or probability sampling (Table 3). Targeted sampling was also used. A total of 59 seroprevalence studies were reported as having been performed so far; most of them were focusing on health care workers (HCW, 20 laboratories out of 30), followed by those on general populations (16 laboratories), schools or other institutions (10/30) and blood donors (8/30). Furthermore, 13 HCW studies included health care workers or other personnel such as cleaners, porters, administrative or laboratory staff in hospitals. Other three HCW studies focused on staff members in contact with SARS-CoV-2 infected patients, 2 studies on a specific ward and other 2 on HCW with a previous laboratory confirmed SARS-CoV-2 infection.

Three laboratories reported the observed seroprevalence among HCW; it was 11% in Belgium, 5% in Denmark and 22% in the Netherlands (Table 3). Five out of the 16 laboratories performing seroprevalence studies on general population reported a seroprevalence ranging from 0.88% in Slovenia to 5.6% in Belgium and 4 of those laboratories reported also the study population size, which varied from 1368 to 18000 people involved. In particular, Slovenia appeared to have a significantly lower seroprevalence when compared with other countries reporting higher seroprevalences (0.88% vs 2.2 in Denmark, $P=0.001$; 0.88% vs 2.9% in Lisbon 2, $P<0.0001$; 0.88% vs 2.75% in Penafiel, $P=0.0001$). This difference was also reflected when compared the estimate number of confirmed COVID-19 positive, that was significantly lower in Slovenia (101-1000 cases) compared with Denmark and Portugal that reported >10000 cases.

Furthermore, 31 laboratories reported the epidemiological information collected with their serological data (Table 5-8). Most of them collected sample date (26 laboratories), patient's age (n = 28), information whether they had a laboratory confirmed SARS-CoV-2 infection and if so, date of diagnosis (n = 26), reported symptoms (n = 22), symptom onset (n = 23) and severity of infection (n = 14) (Table 5). Data collected on severity of infection included whether they were hospitalised (n = 17), the length of their hospitals stay (n = 9) or whether they were admitted to the intensive care (n = 14) (Table 7). Smaller number of laboratories reported data on outcome of the infection (n = 14, Table 6) and the presence of underlining medical conditions (n = 14, Table 8). Data on long-term outcomes was rarely collected; data on on-going SARS-CoV-2 PCR positivity was collected by 8 laboratories whereas only a few laboratories systematically collected data on long-term respiratory, cardiac or neurological issues (n = 2, 1 and 1, respectively; Tables 6, 8).

DISCUSSION

This study reports data on SARS-CoV-2 serological testing from 36 clinical or public health virological laboratories in 20 European countries. Results demonstrate a rapid European-wide hospital-based response to the COVID-19 pandemic we all faced earlier this year. While these largely hospital-based laboratories were diagnosing and controlling over 100.000 patients with SARS-CoV-2 infection based on defined criteria [6], followed by a variety of mitigation and quarantine strategies often affecting also themselves, they managed simultaneously to introduce a battery of different serological assays not only to clinical practice but also to support seroprevalence studies. Our data shows the variety of assays introduced was vast; from viral isolation to in-house testing and commercial assays, containing different antigens and measuring different antibody classes.

However, during the first wave of COVID-19 pandemic, mitigation strategies were broadly applied without strong evidence to support these [8]. All countries and laboratories participating in our study experienced these mitigation strategies including national and local lockdowns and closures of restaurants, schools or other public places. Measures reflected also the health system capacity, such as observed in Bulgaria where the national lockdown lasted throughout the study period despite the small number of reported SARS-CoV-2 cases. On

Table 3. Focus on the seroprevalence studies conducted during the study period by participant laboratories: overview of reported study designs, estimation of seroprevalence calculated and estimation of the number of samples included into each study (when available) and/or overall reported in the last column.

COUNTRY	CITY	SEROPREVALANCE STUDIES										ESTIMATED NUMBER OF SAMPLES INCLUDED
		SCHOOL OR OTHER WORKPLACE		HOSPITAL OR GP ASSOCIATED		BLOOD DONORS		HEALTH CARE WORKERS (HCW)		GENERAL POPULATION		
		Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	
Austria	Vienna	Descriptive cross-sectional	Manuscript submitted	Descriptive cross-sectional	Manuscript submitted	Cohort; Descriptive cross-sectional	Study ongoing	Cohort; Descriptive cross-sectional	Manuscript submitted	Cohort; Descriptive cross-sectional	Manuscript submitted	>5,000
Belgium	Bruges			Cohort of dialysis patients	2.5% [11]			Descriptive cross-sectional	11%	Descriptive cross-sectional	5.6%	
Bulgaria	Sofia	Unknown						Unknown				
Croatia	Zagreb			Targeted				Convenient sampling		Convenient sampling		1.05
Czech Republic	Prague	Descriptive cross-sectional						Unknown				460
Denmark	Copenhagen and Hilleroed							Cohort; Descriptive cross-sectional	5%	Descriptive cross-sectional	2.2%	30000 HCW ~18000 general population
Germany	Kiel									Convenient sampling		
	Freiburg	Unknown	Not reported					Unknown	Not reported			1,000
	Bonn	Unknown	Not reported					Unknown	Not reported			>4000
Greece	Crete					Cohort study	Not reported	Cohort study	Not reported	Cohort study	Not reported	2,000
Ireland	Dublin									SCOPI study [12]		1,733
Italy	Pavia	Descriptive cross-sectional study	Not reported	Unknown	Not reported	Unknown	Not reported	Unknown	Not reported	Unknown	Not reported	5,000
The Netherlands	Tilburg							Cohort study	22%			~140
Norway	Oslo	Unknown				Unknown		Unknown		Unknown		~4500
	Trondheim	Unknown				Unknown		Unknown		Unknown		400
Portugal	Porto					Cohort; Descriptive cross-sectional						525
	Mora	Unknown										250
	Lisbon 2									Convenient sampling	Seroprevalence [2.9% IC95(2.0%-4.2%)] crude; [1.7 IC95(0.0 – 3.3)] adjusted for test sensitivity	2,300
	Porto							Unknown				60
	Penafiel									Convenient sampling	2.7% (only igg was evaluated)	2724

Table 3. Continued

COUNTRY	CITY	SEROPREVALENCE STUDIES										ESTIMATED NUMBER OF SAMPLES INCLUDED
		SCHOOL OR OTHER WORKPLACE		HOSPITAL OR GP ASSOCIATED		BLOOD DONORS		HEALTH CARE WORKERS (HCW)		GENERAL POPULATION		
		Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	Study design	Estimated seroprevalence	
Romania	Bucharest							Cohort study				Not know
Slovenia	Ljubljana 1							Descriptive cross-sectional	Still ongoing			1,200
	Ljubljana 2									Probability sampling	0.9% (late April 2020)	1,368
Spain	Barcelona 1							Unknown				7,848
	Barcelona 2	Cohort study						Descriptive cross-sectional		Unknown		10,000
	Madrid					Cohort study				Unknown		45,000
Sweden	Stockholm							Unknown				
	Lund					Unknown						
Turkey	Istanbul			Descriptive cross-sectional				Cohort; Descriptive cross-sectional				500
	Izmir									Descriptive cross-sectional		3,465
Total		10		5		8		20		16		

Table 4. Estimation of the amount of samples used to perform seroprevalence studies, diagnostic serology, to support convalescent plasma studies or other larger studies by participating laboratories

COUNTRY	CITY	SEROPREVALENCE STUDIES	DIAGNOSTIC	CONVALESCENT PLASMA STUDIES	AS SUPPORT FOR LARGER STUDIES	OTHER PURPOSES
		Estimate No. samples	Estimate No. samples	Estimate No. samples	Estimate No. samples	Estimate No. samples
Austria	Vienna	>5000	~500	~500	Multiple evaluation studies for serological assays in acute infection (n~400) national and local seroprevalence studies (n~5000). Correlation of NT with other assays (n~500). Characterization of reconvalescent plasma (n~500)	
Belgium	Bruges	-	320	-	-	-
Bosnia and Herzegovina	Sarajevo	-	561	-	-	-
Bulgaria	Sofia	-	Number not reported	-	-	-
Croatia	Zagreb	1050	-	-	-	-
Czech Republic	Prague	460	100	50	100	
Denmark 1	Copenhagen	-	-	-	-	-
Denmark 2	Copenhagen and Hilleroed	~10000	-	-	-	-
Germany 1	Kiel		~150	-	-	-
Germany 2	Freiburg	1000	500	100	Number not reported	-
Germany 3	Bonn	>4000	~500	~120	-	-

Table 4. Continued

COUNTRY	CITY	SEROPREVALENCE STUDIES	DIAGNOSTIC	CONVALESCENT PLASMA STUDIES	AS SUPPORT FOR LARGER STUDIES	OTHER PURPOSES
		Estimate No. samples	Estimate No. samples	Estimate No. samples	Estimate No. samples	Estimate No. samples
Greece 1	Thessaloniki	-	-	-	-	To check antibodies kinetics comparing mild and severe cases (70 samples)
Greece 2	Crete	2000			Number not reported	-
Iceland	Reykjavik		Number not reported	Number not reported	-	-
Ireland	Dublin	1733	2285	-	-	-
Italy	Pavia	5000	20000	3900	Correlation of NT with other assays (n~1100) local seroprevalence studies (n~1900). Multiple evaluation studies for serological assays in acute infection (n= ~400)	
The Netherlands	Tilburg	~140*	Number not reported	-	-	Study on the humoral immune response in mildly and severe COVID-19 patients (62 patients, ~180 samples)
Norway 1	Oslo	~4500	~3500	200	Number not reported	
Norway 2	Trondheim		400	150	-	-
Portugal 1	Porto	525	-	-	-	-
Portugal 2	Mora	250	-	-	-	-
Portugal 3	Lisbon 1	-	-	-	-	-
Portugal 4	Lisbon 2	2300	-	-	-	-
Portugal 5	Porto	60	-	-	-	-
Portugal 6	Penafiel	-	2724	-	-	-
Romania	Bucharest	do not known	-	-	-	-
Slovenia 1	Ljubljana 1	1200	-	-	-	-
Slovenia 2	Ljubljana 2	1368	250		3,000	3100 free-market testing
Spain 1	Barcelona 1	7848	-	-	-	-
Spain 2	Barcelona 2	10000	1000	-	-	-
Spain 3	Madrid	45000		~2000	National seroprevalence study (ENE-COVID) (n~150000). Clinical trial of convalescent Plasma Therapy (ConPlas-19) (n~2000). Evaluation of 21 marketed serological assays for determining SARS-CoV-2 IgG or total antibodies (~100 samples/test)	
Sweden 1	Stockholm		37000 during April through June.	Data not available	Data not available	
Sweden 2	Lund	Number not reported	Number not reported	Number not reported	-	-
Turkey 1	Istanbul	160	100	400	-	-
Turkey 2	Izmir	3465	25	325	-	-
Turkey 3	Ankara		1200	50	-	-
Total number of responses		24	22	13	8	4

Table 5. Description of data about patients' information, collected during seroprevalence studies conducted in Europe, March-June 2020

COUNTRY	LABORATORY PERFORMING SEROPREVALENCE STUDIES	DATA COLLECTED DURING SEROPREVALENCE STUDIES									
		PATIENT INFORMATION									Other data/ comments
		Whether laboratory confirmed diagnosis	Whether symptomatic	Whether hospitalised	Which outcome after infection	Presence of underlying disease	Date of symptoms onset	Date of diagnosis	Age	Date of sample collection	
Austria	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
Belgium	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	-
Bosnia and Herzegovina	No	-	-	-	-	-	-	-	-	-	-
Bulgaria	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
Croatia	Yes	Yes	Yes	Yes	No	Yes	Yes		No	Yes	-
Czech Republic	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
Denmark 1	No	-	-	-	-	-	-	-	-	-	-
Denmark 2	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Data on 2 HCW studies, but information not available for general population based study
Germany 1	-	Yes	-	-	-	-	-	Yes	Yes	Yes	-
Germany 2	Yes	Yes	Yes	-	-	Yes	-		Yes	-	-
Germany 3	Yes	-	-	-	-	-	-	-	-	-	-
Greece 1	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
Greece 2	Yes	Yes	Yes	Yes		Yes	Yes		Yes	Yes	-
Iceland	No	-	-	-	-	-	-	-	-	-	-
Ireland	Yes	Yes	Yes	Yes			Yes	Yes	Yes	Yes	-
Italy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
The Netherlands	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
Norway 1	Yes	-	Yes	No	No	No	Yes	Yes	Yes	Yes	-
Norway 2	-	-	-	-	-	-	-	-	-	-	-
Portugal 1	Yes	No	No	No	No	No	No	Yes	Yes	Yes	Only blood donors
Portugal 2	No	Yes	-	Yes	-	-	Yes	Yes	Yes	Yes	Study on residence
Portugal 3	No	-	-	-	-	-	-	Yes	Yes	Yes	-
Portugal 4	Yes	Yes	Yes	No	-	Yes	Yes	Yes	Yes	Yes	-
Portugal 5	Yes	Yes	Yes	Yes	Yes; No	No	Yes	Yes	Yes	Yes	-
Portugal 6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Elderly of nursery homes/residences also studied
Romania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-
Slovenia 1	Yes	Yes	Yes	-	-	Yes	Yes	Yes	Yes	Yes	HCW (including nurses and doctors from 2 regional hospitals)
Slovenia 2	Yes	Yes	Yes	Yes	-	-	Yes	Yes	Yes	Yes	-
Spain 1	Yes	Yes	Yes	Yes	Yes	-	Yes	Yes	Yes	Yes	-
Spain 2	Yes	Yes	Yes		-	-	Yes	Yes	Yes	Yes	-
Spain 3	Yes	Yes	Yes	Yes	Yes	-	Yes	Yes	Yes	Yes	-
Sweden 1	No	-	-	-	-	-	-	-	-	-	-
Sweden 2	Yes	Yes	No	No	No	No	Yes	Yes	Yes	Yes	-
Turkey 1	Yes	Yes	-	Yes	-	-	-	Yes	Yes	Yes	-
Turkey 2	Yes	-	-	-	-	-	-	-	-	-	No details available at the laboratory
Turkey 3	No	-	-	-	-	-	-	-	-	-	-
Total number of responses	25	26	22	21	14	14	23	26	28	27	2

Table 6. Description of outcome data collected during seroprevalence studies conducted in Europe, March-June 2020

COUNTRY	DATA COLLECTED DURING SEROPREVALENCE STUDIES							
	OUTCOME DATA COLLECTED							
	FULLY RECOVERED	RECOVERED BUT STILL RNA POSITIVE	DEATH	LONG TERM RESP ISSUES	LONG TERM CARDIO ISSUES	LONG TERM TIRENESS	LONG TERM NEURO	OTHER OUTCOME/COMMENTS
Austria	Yes	Yes	Yes	-	-	-	-	-
Belgium	Yes	Yes	Yes	-	-	-	-	-
Bosnia and Herzegovina	-	-	-	-	-	-	-	-
Bulgaria	-	Yes	Yes	Yes	-	Yes	-	-
Croatia	-	-	-	-	-	-	-	-
Czech Republic	Yes	-	-	-	-	-	-	-
Denmark 1	-	-	-	-	-	-	-	-
Denmark 2	Yes	-	-	-	-	-	-	For the hospital studies only
Germany 1	-	-	-	-	-	-	-	-
Germany 2	-	-	-	-	-	-	-	-
Germany 3	-	-	-	-	-	-	-	-
Greece 1	-	-	-	-	-	-	-	-
Greece 2	Yes	-	-	-	-	-	-	-
Iceland	-	-	-	-	-	-	-	-
Ireland	-	-	-	-	-	-	-	-
Italy	Yes	Yes	Yes	-	-	-	-	-
The Netherlands	Yes	Yes	-	-	-	-	-	-
Norway 1	-	-	-	-	-	-	-	-
Norway 2	-	-	-	-	-	-	-	-
Portugal 1	-	-	-	-	-	-	-	-
Portugal 2	-	-	-	-	-	-	-	-
Portugal 3	-	-	-	-	-	-	-	-
Portugal 4	-	-	-	-	-	-	-	-
Portugal 5	Yes	-	-	-	-	-	-	-
Portugal 6	Yes	Yes	-	-	-	-	-	-
Romania	Yes	-	Yes	-	-	-	-	-
Slovenia 1	-	-	-	-	-	-	-	-
Slovenia 2	-	-	-	-	-	-	-	-
Spain 1	Yes	Yes	-	-	-	-	-	-
Spain 2	-	-	-	-	-	-	-	-
Spain 3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	ENE-COVID: Data were collected by National Centre for Epidemiology, Institute of Health Carlos III. Con-Plas-19: Data were collected by Hospital Universitario Puerta de Hierro-Majadahonda.
Sweden 1	-	-	-	-	-	-	-	-
Sweden 2	-	-	-	-	-	-	-	Data not collected
Turkey 1	Yes	-	Yes	-	-	-	-	-
Turkey 2	-	-	-	-	-	-	-	No details available at the laboratory
Turkey 3	-	-	-	-	-	-	-	-
Total number of responses	12	8	9	2	1	2	1	2

Table 7. Description of hospitalisation data collected during seroprevalence studies conducted in Europe, March-June 2020

COUNTRY	DATA COLLECTED DURING SEROPREVALENCE STUDIES					
	HOSPITALISATION (NON ICU)	NOT HOSPITALISED	ADMISSION IN ICU	LENGTH OF HOSPITALISATION	NOT KNOWN	OTHER
Austria	Yes	Yes	Yes	Yes	-	-
Belgium	Yes	Yes	Yes	Yes	-	-
Bosnia and Herzegovina	-	-	-	-	-	-
Bulgaria	Yes	Yes	Yes	-	-	-
Croatia	Yes	Yes	-	-	-	Only data about hospitalization (Y/N)
Czech Republic	-	Yes	-	-	-	-
Denmark 1	-	-	-	-	-	-
Denmark 2	Yes	Yes	Yes	Yes	-	For the hospital studies only
Germany 1	-	Yes	-	-	-	-
Germany 2	Yes	Yes	Yes	Yes	-	-
Germany 3	-	-	-	-	-	-
Greece 1	Yes	Yes	Yes	-	Yes	-
Greece 2	Yes	Yes	Yes	-	-	-
Iceland	-	-	-	-	-	-
Ireland	-	-	-	-	-	-
Italy	Yes	-	Yes	Yes	-	-
The Netherlands	Yes	Yes	-	-	-	-
Norway 1	-	-	-	-	-	-
Norway 2	-	-	-	-	-	-
Portugal 1	-	-	-	-	-	-
Portugal 2	-	-	-	-	-	-
Portugal 3	Yes	-	Yes	-	-	-
Portugal 4	-	-	-	-	-	-
Portugal 5	Yes	Yes	-	-	-	-
Portugal 6	-	-	-	-	-	-
Romania	Yes	Yes	Yes	Yes	-	-
Slovenia 1	-	-	-	-	-	-
Slovenia 2	Yes	Yes	Yes	Yes	-	-
Spain 1	-	-	-	-	-	-
Spain 2	Yes	Yes	Yes	Yes	-	-
Spain 3	Yes	Yes	Yes	Yes	Yes	ENE-COVID: Data were collected by National Centre for Epidemiology, Institute of Health Carlos III. ConPlas-19: Data were collected by Hospital Universitario Puerta de Hierro-Majadahonda.
Sweden 1	-	-	-	-	-	-
Sweden 2	-	-	-	-	-	-
Turkey 1	Yes	Yes	Yes	-	-	-
Turkey 2	-	Yes	-	-	-	-
Turkey 3	-	-	-	-	-	-
Total number of responses	17	18	14	9	2	3

Table 8. Description of risk factors data collected and age-groups included in seroprevalence studies conducted in Europe, March-June 2020

COUNTRY	RISKS DATA COLLECTED									AGE-GROUP (YEARS) INCLUDED IN THE STUDY/IES						
	HYPERTENSION	DIABETES	CARDIOVASCULAR DISEASE	CHRONIC RESPIRATORY	CHRONIC KIDNEY	IMMUNE COMPROMISED	CANCER	OBESITY	OTHER	0-4	5-9	10-19	20-59	60-74	75-90	>90
Austria	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-	-	Yes	Yes	Yes	Yes	Yes	Yes
Belgium	-	-	-	-	Yes	-	-	-	HCW	-	-	-	Yes	Yes	Yes	Yes
Bosnia and Herzegovina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bulgaria	-	-	-	-	-	Yes	-	-	Haematological	-	-	-	Yes	Yes	Yes	-
Croatia	-	-	-	-	-	-	-	-	Data not systematically collect	Yes	Yes	Yes	Yes	Yes	Yes	-
Czech Republic	-	-	-	-	-	-	-	-	No criteria of inclusion	-	-	-	Yes	Yes	Yes	-
Denmark 1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Denmark 2	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	For the hospital studies only	-	-	Yes	Yes	Yes	Yes	Yes
Germany 1	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	-
Germany 2	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	Yes	-
Germany 3	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	-
Greece 1	-	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	-
Greece 2	-	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	-
Iceland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ireland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Italy	-	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	-
The Netherlands	-	-	Yes	Yes	-	Yes	Yes	Yes	Questionnaire about risk factors	-	-	-	Yes	Yes	-	-
Norway 1	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	Yes	-
Norway 2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Portugal 1	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	-	-
Portugal 2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Portugal 3	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	-	-	-	-
Portugal 4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Portugal 5	-	-	-	-	-	-	-	-	HCW with previously positive real time PCR were included	-	-	-	Yes	Yes	-	-
Portugal 6	Yes	Yes	Yes	Yes	Yes	-	Yes	-	Questionnaires about risk factors were performed. Elderly from nursery homes/residences were also considered	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Romania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-	-	-	-	Yes	Yes	-	-
Slovenia 1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-	HCW	-	-	-	Yes	Yes	-	-
Slovenia 2	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Spain 1	-	-	-	-	-	-	-	-	-	-	-	-	Yes	-	-	-

Table 8. Continued

COUNTRY	RISKS DATA COLLECTED										AGE-GROUP (YEARS) INCLUDED IN THE STUDY/IES					
	HYPERTENSION	DIABETES	CARDIOVASCULAR DISEASE	CHRONIC RESPIRATORY	CHRONIC KIDNEY	IMMUNE COMPROMISED	CANCER	OBESITY	OTHER	0-4	5-9	10-19	20-59	60-74	75-90	>90
Spain 2	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	Yes
ENE-COVID: Data are collected by National Centre for Epidemiology, Institute of Health Carlos III. ConPlas-19: Data are collected by Hospital Universitario Puerta de Hierro-Majadahonda.																
Spain 3	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	-	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Sweden 1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sweden 2	-	-	-	-	-	-	-	-	-	-	-	Yes	Yes	Yes	Yes	Yes
Turkey 1	-	-	-	-	-	-	-	-	-	-	-	-	-	Yes	-	-
Turkey 2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Turkey 3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total number of responses	6	6	8	8	7	8	8	6	10	8	11	14	26	24	19	9

the contrary, Sweden with over 15 000 SARS-CoV-2 infections, choose to recommend social distancing only including limiting the gatherings to maximum 50 people, working from home and restricting access to care-homes, in line with the ECDC guidance [13]. Along with mitigation strategies, most participating (94%, 34/36) reported also the use of quarantine scheme after a suspected contact with a SARS-CoV-2 positive person, a travel within or beyond the Europe, with the majority of responders indicating 14 days as period of observation as recommended by ECDC [14]. The length of quarantine was also in keeping with suggested SARS-CoV-2 incubation period [15,16]. It is clear from our data that about 80% of regions/countries observed a decrease in the number of reported SARS-CoV-2 cases within the first 60 days of national lockdown.

This pandemic has also demonstrated the fast tempo serological assays are needed, and can be developed, to support investigations into a newly emerged virus, such as SARS-CoV-2 here. To date, 10 months from the first diagnosis in Europe, about 200 commercial assays have been introduced into the European market [17] and the number continues to increase. Although the clinical and research needs for such assays cannot be over-stated, it is important to maintain quality standards in clinical laboratories. For these reasons, we need to consider how the international community can reach out and support the diagnostic laboratories during these challenging times. In our series of laboratories, validation or verification of the assays prior to their introduction into routine work was largely undertaken. However, the number of samples used for the validation was limited in some cases (ie, below 15 in total) and some laboratories did not have access to reference material in order to perform the assay validation. However, their responses indicated understanding of general good laboratory practice. In fact, proper validation prior the use of a new commercial assay should be always performed, but as openly declared from one of participant, during the first pandemic wave laboratories were overwhelmed due to the amount of work requested and hence had to postpone the validation for practical reasons. The guidance on assay validation is limited, but it should also be modified according to specific situation such as pandemic. Furthermore, informal hospital-based laboratory networks should be encouraged as they can be a source of technical and material support during difficult times, like this pandemic.

Although we did not aim to evaluate the results obtained by different serological assays in this study, it is vital to point out that the sensitivity and specificity of available SARS-CoV-2 serological assays varies hugely [18]. For example, the sensitivity of some most commonly used assays does not reach even 80% [19]. However, serological assays have different require-

ment depending on their purpose. Whereas the ease of use might be the most important criteria if an assay is being used for a large-scale seroprevalence work, sensitivity is a key marker for any assay used diagnostically. Any assay used to screen convalescent plasma donors should be predictive of high neutralising antibody levels. Anticipated SARS-CoV-2 vaccine introduction into routine use will set up further requirements for serological assays used, especially when we need to evaluate separately vaccine-produced and natural immunity. This would mean that laboratories may need to consider setting up at least two serological assays, one focusing on antibodies directed against spike protein and another against nucleocapsid proteins. Based on our data, over half of laboratories participating to our study do not currently have both of these assays available, but by introducing an additional test they could easily support the introduction of vaccine.

More than half of participating laboratories performed one or more seroprevalence studies, mostly focusing on specific population such as health care workers and blood donors. With these studies, information on age, date of sample collection and diagnosis were almost always gathered, whereas the outcome data and information on underlying diseases were less frequently collected. [20]. This could be a limitation in understanding risk factors driving a different immunological response. In fact, despite it is quite clear that the presence of some diseases can increase the risk of severe outcomes [18], their role in the immune response remain unclear [21]. Although our current understanding of immunological responses to SARS-CoV-2 including the durability of the antibody response and occurrence of seroreversion remains uncertain [22,23], continuation of seroprevalence studies collecting more information of medical conditions is highly recommended. Such studies will provide better understanding of the pandemic course in the coming months in the absence of a protective vaccine and the necessity to target public health measures to specific populations at highest risk.


Estimation of seroprevalence in general population was reported by five participant laboratories in this study, and similarly seroprevalence among HCW was reported by three participant laboratories only. Although it was clear, that seroprevalence was higher among the HCW than in general population, confirming the previous observations [24], it is not possible to draw further conclusions from these data. We collected only limited information about the characteristics of the study population (ie, age, symptoms), details about the serological test used (ie, manufacturer, antigen and antibody subclass) and the dates of study. Although the same limitations applied to the population-based seroprevalence studies reported here, the seroprevalence estimates were in line with the number of SARS-CoV-2 infections reported during the same period from the same region hence reflecting the country-based situation well.

We have described the SARS-CoV-2 serological testing introduced and undertaken across the 36 different European laboratories during the first pandemic wave, when there was the urge to understand the seroprevalence of affected populations, the length of immunity acquired during SARS-CoV-2 infections and its likely protective effects. This understanding is still required and would likely support the public health decision making and drive evidence-based mitigation and infection control strategies.

CONCLUSION

This is the first paper, to our knowledge, gathering the information available in the European region about the use of serological testing during the first pandemic wave. The study documents the high level of hospital-laboratory involvement in serological response across European countries during the first pandemic wave: serology methods were rapidly implemented by many hospital laboratories and served as an important diagnostic supplement while the molecular diagnostic capacity increased during these early months of the first pandemic wave.

Note added in proof: The probability-based seroprevalence study in Slovenia (Table 3, Ljubljana 2) is now published [25].



ESCV & ENPEN study group collaborators: **Austria:** Lukas Weseslindtner (Center for Virology, Medical University Vienna, Austria), Elisabeth Spuchhammer-Stöckl (Center for Virology, Medical University Vienna, Austria); **Belgium:** Reynders Marijke (Department of Laboratory Medicine, Medical Microbiology, AZ Sint-Jan Bruges-Ostend AV, Belgium); **Bosnia and Herzegovina:** Amela Dedeic Ljubovic (Department of Clinical microbiology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina); **Bulgaria:** Dora Aleksandrova (Department of Clinical Virology, National Specialized Hospital for Active Treatment of Haematologic Diseases, Sofia, Bulgaria); **Croatia:** Irena Tabain (Virology Department; Croatian Institute of Public Health, Zagreb, Croatia); **Czech Republic,** Petra Rainetová (National Institute of Public Health, Czech Rep); Helena Jirincova (National Institute of Public Health, Czech Rep); **Denmark,** Didi Bang (Department of Clinical Microbiology, Copenhagen University Hospital Hvidovre, Denmark); **Germany:** Helmut Fickenscher (Institute for Infection Medicine, University of Kiel and University Medical Center Schleswig-Holstein); Andi Krumbholz (Institute for Infection Medicine, University of Kiel and University Medical Center Schleswig-Holstein); Marcus Panning

(Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany); Daniela Huzly (Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany); Anna M. Eis-Hübinger (Institute of Virology, University Hospital, University of Bonn, Bonn, Germany); **Greece:** Anna Papa (Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece); George Sourvinos (Laboratory of Clinical Virology, Medical School, University of Crete, Herakleion, Crete, Greece); Alexandros Zafiropoulos (Laboratory of Clinical Virology, Medical School, University of Crete, Herakleion, Crete, Greece); **Iceland:** Ásgeir Erlendur Ásgeirsson (Department of Clinical Microbiology Landspítali-National University Hospital of Iceland); **Ireland:** Jeff Connell (University College Dublin, National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4); **Italy:** Elena Percivalle (Molecular Virology Unit, Department of Microbiology and Virology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy); Irene Cassaniti (Molecular Virology Unit, Department of Microbiology and Virology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy); **Netherlands:** Couderé Karen (Microvida, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands); **Norway:** Andreas Lind (Department of Microbiology, Oslo University Hospital, Oslo, Norway); Svein Arne Nordbø (Department of Medical Microbiology, St. Olavs University Hospital, Trondheim, Norway and Department of Clinical; Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway); **Portugal:** Maria de São José Nascimento (Faculty of Pharmacy, University of Porto, Porto, Portugal), João Rodrigo Mesquita (Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto, Portugal); Carlos Sinogas (Évora University, Biology Department); Maria Brito (Infectious Pediatric Unit, Department of Pediatrics, Hospital de Dona Estefânia, CHULC, Lisbon, Portugal); Raquel Guiomar (Infectious Diseases Department, National Institute of Health Dr Ricardo Jorge, Lisbon, Portugal), Daniela Fonseca e Silva (Instituto Português de Oncologia Francisco Gentil Porto, E.P.E, Porto, Portugal), Ana Abreu (Director of the Laboratory of Clinical Analysis Vale do Sousa), Paulo Dessa (Laboratório de Análises Clínicas Vale do Sousa, Penafiel, Portugal); **Romania:** Corneliu Petru Popescu (Carol Davila University of Medicine and Pharmacy, Bucharest, Romania), Victor Babes (Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania); **Slovenia:** Natasa Berginc (National Laboratory for Health, Environment and Food, Laboratory for Public Health Virology, Ljubljana, Slovenia), Katarina Prosenc Trilar (National Laboratory for Health, Environment and Food, Laboratory for Public Health Virology, Ljubljana, Slovenia), Mario Poljak (Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia); **Spain:** Núria Rabella (Virology Unit, Department of Clinical Microbiology, Hospital Universitari de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain), Juliana Esperalba (Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain), Mayte Pérez-Olmeda (Serology Laboratory, National Center of Microbiology, Institute of Health Carlos III, Madrid, Spain), Aurora Fernández-García (Serology Laboratory, National Center of Microbiology, Institute of Health Carlos III, Madrid, Spain); Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain); **Sweden:** Gordana Bog-danovic (Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden), Sandra Muschiol (Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden), Claus Bohn Christiansen (Department of Clinical Microbiology, Medical Service, Region Skåne, Lund, Sweden); **Turkey:** Rabia Can Sannog-lu (Department of Medical Microbiology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey), Aysegul Karahasan Yagci (Department of Medical Microbiology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey), Aysin Zeytinoglu (Department of Medical Microbiology, Ege University Medical Faculty, Izmir, Turkey), Mehmet Soylu (Department of Medical Microbiology, Ege University Medical Faculty, Izmir, Turkey), Burcin Sener (Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey), Alpaslan Alp (Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey).

Acknowledgements: Approval from an ethics committee and informed consent for virus detection and data publication were not required since data were reported as aggregate and anonymous. All authors and study group authors declared the access to the data and the permission to share their content for the publication. We acknowledge the support of ESCV (European society for Clinical virology) in granting a research fellowship, with no involvement in data analysis, drafting of the manuscript and publication. Laboratories' authors would like to thank and acknowledge: **Germany:** Kiel: We would like to acknowledge the work of Annabelle Strömer and Ruben Rose. Freiburg: The study was funded by the Federal Ministry of Education and Research (grant No. 01KI1722 to MP). **Greece:** Crete: Funded by the National Public Investment Program of the Ministry of Development and Investment / General Secretariat for Research and Technology in the framework of the Flagship Initiative to address SARS-CoV-2 (2020ΣΕ01300001). **Portugal:** Porto 1: MSJN and JRM would like to thank Fundação para a Ciência e para a Tecnologia for project "SARS-CoV-2 and blood donation safety in Portugal: a shift to screening? - SARSBLOODsafe" (ref 021_596187412) under the call RESEARCH 4 COVID-19. Porto 2: CS would like to thank the laboratory staff of Virology Department IPOFGP, Porto, Portugal. Portugal 3: MB would like to thank the laboratory staff of Centro Hospitalar Lisboa Central, Lisbon, Portugal. **Romania:** To laboratory staff of Victor Babes Hospital, Bucharest, Romania. **Spain:** Barcelona: All staff from Clinical Laboratory of Vall d'Hebron Hospital Universitari, Barcelona, Spain. Madrid: 1) ENE-COVID Study Group (work supported by the Spanish Ministry of Health, the Institute of Health Carlos III (Ministry of Science and Innovation), and the National Health System. 2) ConPlas-19 Study Group (work supported by the Institute of Health Carlos III (Ministry of Science and Innovation)).

Funding: ESCV granted a research fellow to support data collection and elaboration.

Authorship contributions: HH and TKF contributed to the study conception and design. Material preparation, data collection and analysis were performed by LB, such as the first draft of the manuscript. TKF, PS, HH critically revised the data and manuscript. All study group authors commented on previous versions of the manuscript, collected and shared data from their laboratories, checking the content of the manuscript. All authors read and approved the final manuscript.

Competing interests: The authors completed the ICME Unified Competing Interest form (available upon request from the corresponding author) and declare no conflict of interest.

- 1 European Centre of Disease Control. Number of cases and deaths in Europe. Available: <https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases>. Accessed: 15 April 2021.
- 2 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;323:2052-9. Erratum in: *JAMA*. 2020;323:2098. Medline:32320003 doi:10.1001/jama.2020.6775
- 3 Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. *Nat Commun*. 2020;11:5744. Medline:33184284 doi:10.1038/s41467-020-19481-7
- 4 Istituto Nazionale di Statistica (ISTAT). Available: <https://www.istat.it/it/archivio/246156>. Accessed: 15 April 2021.
- 5 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet*. 2020;396:535-44. Medline:32645347 doi:10.1016/S0140-6736(20)31483-5
- 6 World Health Organization. Case number dashboard. Available: <https://covid19.who.int/> Accessed: 15 April 2021.
- 7 Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. *Transfus Med*. 2020. Online ahead of print. Medline:33333627 doi:10.1111/tme.12746
- 8 Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ*. 2020;370:m2516. Medline:32611558 doi:10.1136/bmj.m2516
- 9 Strömer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T, et al. Kinetics of nucleo- and spike protein-specific immunoglobulin G and of virus-neutralizing antibodies after SARS-CoV-2 infection. *Microorganisms*. 2020;8:1572. Medline:33066057 doi:10.3390/microorganisms8101572
- 10 Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus neutralisation assay for SARS-CoV-2. *Emerg Microbes Infect*. 2020;9:680-6. Medline:32207377 doi:10.1080/22221751.2020.1743767
- 11 De Vriese AS, Reynders M. IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis. *Am J Kidney Dis*. 2020;76:440-1. doi:10.1053/j.ajkd.2020.05.009. Medline:32512038
- 12 Ireland HSE. <https://www.hse.ie/eng/services/news/newsfeatures/scopi-covid-19-research-project/> Accessed: 15 April 2021.
- 13 ECDC. mitigation strategies: <https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-guidelines-non-pharmaceutical-interventions-september-2020.pdf> Accessed: 15 April 2021.
- 14 ECDC quarantine strategies. Available: https://www.ecdc.europa.eu/sites/default/files/documents/Leaflet-Covid-19_Isolation-and-quarantine.pdf. Accessed: 15 April 2021.
- 15 Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. *Euro Surveill*. 2020;25:2000062. Medline:32046819 doi:10.2807/1560-7917.ES.2020.25.5.2000062
- 16 Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. *JAMA*. 2020 323:2085-86. Medline:32293646 doi:10.1001/jama.2020.6266
- 17 European Commission. Annex 1: commercial devices, type Immunoassay. Available: <https://ec.europa.eu/docsroom/documents/40805>. Accessed: 15 April 2021.
- 18 FIND. comparison of commercial serological assay <https://www.finddx.org/covid-19/sarscov2-eval-antibody/> Accessed: 9 January 2021.
- 19 Haselmann V, Özçürümez MK, Klawonn F, Ast V, Gerhards C, Eichner R, et al. Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing. *Clin Chem Lab Med*. 2020;58:2121-30. Medline:32853163 doi:10.1515/cclm-2020-1183
- 20 Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. *Clin Infect Dis*. 2020. Online ahead of print. Medline:32945846
- 21 Sattler A, Angermair S, Stockmann H, Heim KM, Khadzhynov D, Treskatsch S, et al. SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition. *J Clin Invest*. 2020;130:6477-89. Medline:32833687 doi:10.1172/JCI140965
- 22 Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*. 2020;181:1489-1501.e15. Medline:32473127 doi:10.1016/j.cell.2020.05.015
- 23 Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. *Nature*. 2020;587:270-4. Medline:32726801 doi:10.1038/s41586-020-2598-9
- 24 Piccoli L, Ferrari P, Piumatti G, Jovic S, Fernandez Rodriguez B, Mele F, et al. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. *Lancet Regional Health – Europe*. 2021;1:100013. doi:10.1016/j.lanepe.2020.100013
- 25 Poljak M, Oštrbenk Valenčak A, Štrumbelj E, Maver Vodičar P, Vehovar V, Resman Rus K, et al. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned. *Clin Microbiol Infect*. 2021. Online ahead of print. Medline:33838303 doi:10.1016/j.cmi.2021.03.009